1 patent currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2041. from the record
Of the 15 now held by other companies, 10 name Pierre Fabre Médicament SAS as their current owner, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2041
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Oct 2040 · High confidence
The most cited patent in this portfolio, cited by 7 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2040.
now held by Pierre Fabre Médicament, SAS
Also notable
Ends Apr 2040 · High confidence
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
now held by Pierre Fabre Médicament, SAS
Also notable
Ends Feb 2043 · High confidence
The newest of the three, granted 2023. It anchors the portfolio to 2043, later than anything else here.
now held by Mosaica Medicines, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 term has ended since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitors of Fibroblast Growth Factor Receptor Kinases | 1 in force | to Jun 2041 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,345,681 | Inhibitors of Fibroblast Growth Factor Receptor Kinases In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 15 patents in force now held by others · 4 patents ended · 6 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.